Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- National MS Center Melsbroek
- Enrollment
- 250
- Locations
- 2
- Primary Endpoint
- Clinical evidence for active disease
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The goal of this longitudinal study is to (1) explore the association between the gut microbiota and inflammatory disease activity in early onset multiple sclerosis, (2) investigate whether/how gut microbial composition vary when patients experience a relapse, and (3) to assess whether the gut microbiota shows increased similarities between affected pairs of first-degree relatives within the same family when compared with discordant pairs of first-degree relatives.
Detailed Description
Using metagenomics, as well as clinical, immunological, and radiological observations, the investigators will investigate if active relapsing-remitting multiple sclerosis patients have a more pro-inflammatory gut microbiota signature than multiple sclerosis patients with less active disease and matched healthy controls. More specifically, the investigators will investigate whether temporal variability of the gut microbiota is related to inflammatory disease activity in multiple sclerosis, whether changes in the gut microbiota are predictive of future inflammatory disease activity in multiple sclerosis, and whether gut microbiota characteristics are predictive of the disease course after 2 years.
Investigators
Marie D'hooghe
Prof. Dr.
National MS Center Melsbroek
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Clinical evidence for active disease
Time Frame: 3 years
Time to first relapse (after baseline) will be reported for all patients.
Secondary Outcomes
- Radiological evidence for active disease(3 years)